Global Retinal Disorders Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

Description

List of Tables

The global demand for Retinal Disorders Treatment Market is presumed to reach the market size of nearly USD 45.06 Billion by 2032 from USD 19.39 Billion in 2023 with a CAGR of 9.82% under the study period 2024-2032.

The retina is a sensitive layer of tissue located at the back end of the eyes and is responsible for light sensing and transferring images to the brain, any form of the retinal disorder may damage this delicate tissue and affect vision, and, in severe cases, lead to blindness. Retinal disorders may be genetic or age-related, causing degenerative changes in vision. However, a retinal examination is the first step in diagnosing the potential disease and genetic testing for retinal genetic disorders.

MARKET DYNAMICS

The rise in adult and diabetic patient's population across the globe will boost the retinal disease therapeutics market. In addition, the increase in R&D activities in developing countries is bound to boost the market growth globally as the prevalence of the retinal disorder is increasing in both developed and developing regions. Further, the rise in the support offered by government and non-profitable organizations may have a positive impact on the market. In addition, various pipeline products for retinal disorder treatment will also propel the global retinal disease therapeutics market to grow. However, the high cost of retina treatment therapies and patient complaints as having experienced short-term side effects and long-term complications as infection and inflammation after laser eye treatment may affect the global retinal disease therapeutics market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Retinal Disorders Treatment. The growth and trends of Retinal Disorders Treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Retinal Disorders Treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

Macular Degeneration
Dry Macular Degeneration
Wet Macular Degeneration
Diabetic Retinopathy
Others

By Dosage

Gels
Eye Solutions
Capsules & Tablets
Eye Drops
Ointments

By Distribution Channel

Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
Retinal Disorder Treatment

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Retinal Disorders Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Retinal Disorders Treatment market include Santen Pharmaceutical Co. Ltd., Regeneron Pharmaceuticals Inc., Graybug Vision Inc., Shire (Takeda Pharmaceutical Company Limited), Bayer AG, Genentech Inc., Acucela Inc., Pfizer Inc., Kubota Pharmaceutical Holdings Co. Ltd., Allergan Plc. (AbbVie Inc.). This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR11215030

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. RETINAL DISORDERS TREATMENT - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Type
- 3.7.2 Market Attractiveness Analysis By Dosage
- 3.7.3 Market Attractiveness Analysis By Distribution Channel
- 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL RETINAL DISORDERS TREATMENT MARKET ANALYSIS BY TYPE

5.1. Overview By Type
5.2. Historical and Forecast Data
5.3. Analysis By Type
5.4. Macular Degeneration Historic and Forecast Sales By Regions
5.5. Dry Macular Degeneration Historic and Forecast Sales By Regions
5.6. Wet Macular Degeneration Historic and Forecast Sales By Regions
5.7. Diabetic Retinopathy Historic and Forecast Sales By Regions
5.8. Others Historic and Forecast Sales By Regions

6. GLOBAL RETINAL DISORDERS TREATMENT MARKET ANALYSIS BY DOSAGE

6.1. Overview By Dosage
6.2. Historical and Forecast Data
6.3. Analysis By Dosage
6.4. Gels Historic and Forecast Sales By Regions
6.5. Eye Solutions Historic and Forecast Sales By Regions
6.6. Capsules & Tablets Historic and Forecast Sales By Regions
6.7. Eye Drops Historic and Forecast Sales By Regions
6.8. Ointments Historic and Forecast Sales By Regions

7. GLOBAL RETINAL DISORDERS TREATMENT MARKET ANALYSIS BY DISTRIBUTION CHANNEL

7.1. Overview By Distribution Channel
7.2. Historical and Forecast Data
7.3. Analysis By Distribution Channel
7.4. Hospital Pharmacy Historic and Forecast Sales By Regions
7.5. Online Pharmacy Historic and Forecast Sales By Regions
7.6. Retail Pharmacy Historic and Forecast Sales By Regions
7.7. Retinal Disorder Treatment Historic and Forecast Sales By Regions

8. GLOBAL RETINAL DISORDERS TREATMENT MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE RETINAL DISORDERS TREATMENT COMPANIES

9.1. Retinal Disorders Treatment Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF RETINAL DISORDERS TREATMENT INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. Santen Pharmaceutical Co. Ltd.
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. Regeneron Pharmaceuticals Inc.
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. Graybug Vision Inc.
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. Shire (Takeda Pharmaceutical Company Limited)
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. Bayer AG
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. Genentech Inc.
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. Acucela Inc.
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. Pfizer Inc.
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. Kubota Pharmaceutical Holdings Co. Ltd.
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. Allergan Plc. (AbbVie Inc.)
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies